Status:
NOT_YET_RECRUITING
Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients
Lead Sponsor:
Yale University
Collaborating Sponsors:
American Society for Metabolic and Bariatric Surgery
Conditions:
Obesity
Smoking Cessation
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this research study is to develop and pilot a multiple health behavior change intervention for weight loss and smoking cessation using medication (Naltrexone + Bupropion) and behavior t...
Detailed Description
Smoking prevalence among pre-bariatric surgery patients is estimated to be as high as 40%. In addition to quitting smoking, patients are expected to lose weight before surgery, which is challenging as...
Eligibility Criteria
Inclusion
- Be actively considering bariatric surgery.
- Smoke at least 5 cigarettes daily for the past 3 months.
- Have a BMI ≥ 30.0 kg/m2.
- Not currently taking medications that interact with Naltrexone or Bupropion (e.g., opiates, benzodiazepines).
- No history of medical conditions that are contraindicated with Naltrexone or Bupropion (e.g., seizure disorders, uncontrolled hypertension, cardiac issues including history of heart attacks, heart disease, or stroke, history of anorexia or bulimia nervosa).
- Physically well enough to participate in the intervention (e.g., able to walk independently).
- Speak/read/write in English.
- Be 18-65 years old.
- Not currently pregnant or breastfeeding or have plans to become pregnant or breastfeed during the study.
- No active suicidal or homicidal ideation.
Exclusion
- Has a predisposition to seizures (e.g., subject with a history or evidence of seizure disorder, febrile seizures during childhood, brain tumor, cerebrovascular disease, or significant head trauma; has a family history of idiopathic seizure disorder or is currently being treated with medications or treatment regimens that lower seizure threshold).
- Has a history of anorexia nervosa or history of bulimia nervosa.
- Is currently taking a medication that is contraindicated to Naltrexone or Bupropion (e.g., MAOIs, opiates).
- Has a history of allergy or sensitivity to Naltrexone or Bupropion.
- Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression).
- Has untreated hypertension with a seated systolic blood pressure \> 160 mmHg, diastolic blood pressure \> 100 mmHg, or heart rate \> 100 beats/minute.
- Has a history of congenital heart disease, cardiovascular disease, cardiac arrhythmias requiring medication, or a history of cerebrovascular pathology including stroke.
- Has current uncontrolled Type I or Type 2 diabetes mellitus.
- Has a history of severe renal, hepatic, neurological, chronic pulmonary, or gallbladder disease, or any other unstable medical disorder.
- Is breast-feeding or is pregnant or is not using a reliable form of birth control.
- Reports active suicidal or homicidal ideation.
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07224087
Start Date
January 1 2026
End Date
December 31 2027
Last Update
November 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06511